Strength Training Response of Muscle in GLP-1 Users
ConditionMuscle Mass
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorVirginia Polytechnic Institute and State University
About this trial
GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age, 50y+
Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less
Weight <300 lb
Pass a health and exercise readiness screening
Disqualifiers
Age <50
Weight >300 lb
Osteoporosis
Active metabolic, neoplastic, or cardiovascular disease
Trial design
Design model
Parallel
Treatments tested in this trial
Strength Training
BehavioralParticipants taking a GLP-1 will undergo a 14-week strength training regimen to determine changes in muscle mass. They will perform a series of resistance training exercises supervised by a personal trainer on 3 days per week.
Wait first, then strength training
Other interventionParticipants will be waitlisted and receive the 14-week strength training intervention at the end of the waitlist period. During the waitlist period, participants will get no intervention and then be offered the strength training intervention after the first 14 weeks.
Treatment groups
30 Participants
are divided into 2 treatment groupsGroup A: Strenth TrainingExperimental treatment 1 intervention
Group B: Waitlisted controlOther 1 intervention
Trial outcomes
Primary outcomes
1
Muscle mass by d3-creatine dilution
Participants will collect a urine sample prior to be provided a creatine capsule containing 30 milligrams of a naturally-occurring creatine isotope. A glass of water will be provided to wash it down. Participants will be asked to return \~3 days later to provide another urine sample. Urine samples will be analyzed at an off-site laboratory to determine changes in d3-creatine excretion before and after the 14-week strength training intervention.
Time frame
Water containing creatine isotope consumed in lab; Urine sample collection on Day 0 and Day 3 at baseline and 14 weeks.2
Balance testing - Percentage of failed recoveries
Participants will stand on the treadmill with the belt stationary. The belt will then suddenly change to a speed specified by the investigator, and the participant will attempt to step to maintain their balance and establish a stable gait. In addition to the treadmill itself, this system includes an integrated fall arrest harness that is anchored to an overhead gantry that is fixed to the treadmill. This harness prevents any body part but the feet from impacting the treadmill in the event that the participant is unable to maintain their balance after a sudden change in speed.
Time frame
2-hour testing session in lab at baseline and 14 weeks.Secondary outcomes
1
Muscle function
Participants will walk 500 meters down and back along a hallway at a self-selected pace. The walk will be measured, supervised, and timed by lab personnel.
Time frame
500-meter timed walk in lab at baseline and 14 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov